Could an arthritis drug shield heart and kidneys in metabolic syndrome?

NCT ID NCT07704190

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests whether secukinumab, a drug that blocks inflammation, can reduce the risk of major heart problems and kidney decline in people with cardiorenal metabolic syndrome and hardened arteries. About 100 adults will receive either secukinumab injections plus standard care, or standard care alone, and be followed for two years. The main goal is to see if the drug delays heart attacks, strokes, or heart-related death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
secukinumab, an injectable drug that blocks IL-17A to reduce inflammation
What this could lead to
If successful, this could show that targeting inflammation with secukinumab lowers the risk of heart attacks, strokes, and kidney decline in people with metabolic syndrome and heart disease.
What could go wrong
This is a small, early-phase trial with only 100 participants, so results may not apply broadly. The drug may not improve outcomes and could have side effects like infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.